// App-Quantinova.ai

P4-01-12 : Circulating tumor cells (CTC) and endothelial cells (CEC) changes in HER2 negative metastatic breast cancer (MBC) patients treated with first line weekly paclitaxel and bevacizumab: Preliminary results of a prospective cohort from the French Breast Cancer InterGroup Unicancer: COMET study

Researchers

Presenter

  • Pierga J-Y

Principal Investigators

  • Vaucher I

  • Gutierrez M

  • Luporsi E

  • Mouret-Reynier M-A

  • Dalenc F

  • Asselain B

  • Lemonnier J

  • Bidard F-CTredan OGuiu S

  • Romieu G

  • Goncalves A

  • Debled M

  • Levy C

  • Ferrero J-M

  • Jouannaud C

Medical Centers

  • Center Georges-Francois Leclerc, Dijon, France

  • Institut Jean-Godinot, Reims, France

  • Centre Francois Baclesse, Caen, France

  • Institut Claudius Regaud, Toulouse, France

  • Institut Curie, Saint-Cloud, AB, France

  • R&D UNICANCER, Paris, FranceInstitut Bergonie, Bordeaux, FranceCentre Antoine Lacassagne, Nice, France

  • Centre Jean Perrin, Clermont-Ferrand, France

  • Centre Leon Berard, Lyon, France

  • Institut Paoli-Calmettes, Marseille, France

  • CRLC Val d'Aurelle, Montpellier, France

  • Institut Curie, Paris Cedex, France

  • Centre Alexis Vautrin, Vandoeuvre-Les-Nancy, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

  • Circulating DNA

Drug/Treatment

  • Bevacizumab

  • Paclitaxel

  • Alora

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved